Howard S. Oster

1.5k total citations
55 papers, 925 citations indexed

About

Howard S. Oster is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Howard S. Oster has authored 55 papers receiving a total of 925 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 10 papers in Genetics and 9 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Howard S. Oster's work include Acute Myeloid Leukemia Research (15 papers), Erythropoietin and Anemia Treatment (12 papers) and Hematological disorders and diagnostics (8 papers). Howard S. Oster is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Erythropoietin and Anemia Treatment (12 papers) and Hematological disorders and diagnostics (8 papers). Howard S. Oster collaborates with scholars based in Israel, United States and Germany. Howard S. Oster's co-authors include Yoram Rudy, Moshe Mittelman, Robert L. Lux, Philip R. Ershler, B Taccardi, Drorit Neumann, Michael A. Hoffman, D.B. Olsen, Joseph D. Andrade and D. L. Coleman and has published in prestigious journals such as Circulation, Blood and International Journal of Molecular Sciences.

In The Last Decade

Howard S. Oster

51 papers receiving 905 citations

Peers

Howard S. Oster

CCM

HEMAT

RNMI

EEE

Giorgio Soardo Italy

Gretta H. Jacobs United States

Erik H. Strøm Norway

Tal Hasin Israel

John S. MacGregor United States

Hanah Kim South Korea

Takahiro Fukuhara Japan

J. Radermacher Germany

Masahiro Iio Japan

Ivan W. Brown United States

Giorgio Soardo Italy

Howard S. Oster

307 ×0.9

CCM

83 ×0.3

HEMAT

37 ×0.3

RNMI

117 ×1.2

EEE

35 ×0.4

Citations per year, relative to Howard S. Oster Howard S. Oster (= 1×) peers Giorgio Soardo

Countries citing papers authored by Howard S. Oster

Since Specialization

Citations

This map shows the geographic impact of Howard S. Oster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard S. Oster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard S. Oster more than expected).

Fields of papers citing papers by Howard S. Oster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard S. Oster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard S. Oster. The network helps show where Howard S. Oster may publish in the future.

Co-authorship network of co-authors of Howard S. Oster

This figure shows the co-authorship network connecting the top 25 collaborators of Howard S. Oster. A scholar is included among the top collaborators of Howard S. Oster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard S. Oster. Howard S. Oster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hausman, R., et al.. (2025). Neutropenia (even mild) and anemia are poor prognostic factors in myelodysplastic syndromes. Frontiers in Medicine. 12. 1558585–1558585.

Oster, Howard S., Arjan A. van de Loosdrecht, & Moshe Mittelman. (2024). Diagnosis of myelodysplastic syndromes: the classic and the novel. Haematologica. 110(2). 300–311. 2 indexed citations

Oster, Howard S. & Moshe Mittelman. (2024). How we diagnose Myelodysplastic syndromes. Frontiers in Oncology. 14. 1415101–1415101. 1 indexed citations

Oster, Howard S., et al.. (2023). Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation. Mediterranean Journal of Hematology and Infectious Diseases. 15(1). e2023044–e2023044. 1 indexed citations

Ben‐Ezra, Jonathan, et al.. (2023). Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes – A potential prognostic marker?. Frontiers in Oncology. 12. 988998–988998.

Oster, Howard S., et al.. (2022). Serum Hypoalbuminemia Is a Long-Term Prognostic Marker in Medical Hospitalized Patients, Irrespective of the Underlying Disease. Journal of Clinical Medicine. 11(5). 1207–1207. 25 indexed citations

Mittelman, Moshe, Noam Barda, Noa Dagan, et al.. (2021). Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 139(10). 1439–1451. 43 indexed citations

Joffe, Erel, Uri Greenbaum, Kalman Filanovsky, et al.. (2020). Kinetics of pre‐myelodysplastic syndromes blood values correlate with disease risk and survival. Hematological Oncology. 38(5). 782–791. 1 indexed citations

Ben‐Califa, Nathalie, Sahar Hiram‐Bab, Tamar Liron, et al.. (2020). Erythropoietin receptor in B cells plays a role in bone remodeling in mice. Theranostics. 10(19). 8744–8756. 19 indexed citations

10.

Greenbaum, Uri, Erel Joffe, Kalman Filanovsky, et al.. (2018). Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. European Journal Of Haematology. 101(4). 502–507. 8 indexed citations

11.

Mittelman, Moshe, Kalman Filanovsky, Yishai Ofran, et al.. (2016). Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol. Annals of Hematology. 95(11). 1811–1818. 5 indexed citations

12.

Oster, Howard S., Ora Halutz, Esther Shabtai, et al.. (2012). Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients. Experimental Hematology. 41(2). 167–171. 10 indexed citations

13.

Oster, Howard S., Drorit Neumann, Michael A. Hoffman, & Moshe Mittelman. (2012). Erythropoietin: The swinging pendulum. Leukemia Research. 36(8). 939–944. 26 indexed citations

14.

Mittelman, Moshe, Howard S. Oster, Michael A. Hoffman, & Drorit Neumann. (2010). The lower risk MDS patient at risk of rapid progression. Leukemia Research. 34(12). 1551–1555. 33 indexed citations

15.

Gillissen, Adrian, et al.. (2007). Clinical efficacy of short-term treatment with extra-fine HFA beclomethasone dipropionate in patients with post-infectious persistent cough.. PubMed. 58 Suppl 5(Pt 1). 223–32. 19 indexed citations

16.

Gillissen, Adrian, et al.. (2007). Efficacy and safety of once or twice daily inhalation of extrafine HFA beclomethasone dipropionate in patients with mild to moderate asthma.. PubMed. 58 Suppl 5(Pt 1). 233–41. 6 indexed citations

17.

Mittelman, Moshe, et al.. (2004). Erythropoietin has an anti‐myeloma effect – a hypothesis based on a clinical observation supported by animal studies. European Journal Of Haematology. 72(3). 155–165. 32 indexed citations

18.

Oster, Howard S. & Yoram Rudy. (1997). Regional regularization of the electrocardiographic inverse problem: a model study using spherical geometry. IEEE Transactions on Biomedical Engineering. 44(2). 188–199. 17 indexed citations

19.

Oster, Howard S. & Yoram Rudy. (1992). The use of temporal information in the regularization of the inverse problem of electrocardiography. IEEE Transactions on Biomedical Engineering. 39(1). 65–75. 78 indexed citations

20.

Oster, Howard S., et al.. (1980). The modern view of beryllium toxicity.. 15(11). 270–275. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact